本次共有来自45个国家和地区的20733名嘉宾参会参展。44家世界500强、中国500强、中国民营500强、 大型跨国公司高管，以及国际组织、中外知名商协会、采购商代表等参会，国际化水平持续提升。 在长春东北亚国际博览中心，中外汽车及零部件、石化、轨道交通等领域最新发展成果，卫星、碳纤 维、生物制药、氢能等领域最新产品，人工智能全生态链、智能机器人、航空材料及零部件、智能控制 系统、低空经济等领域最新技术集中亮相，为产业升级注入新动能。 东北亚博览会执委会副主任、吉林省政府副秘书长马坚介绍，博览会秉持"以展促贸、以会促投"办会理 念，聚焦产业和项目对接，注重经贸与人文交流，共举办主体活动、主题活动和系列活动34场，构建多 层级、宽领域的交流机制。 其间，成功举办的俄罗斯商务日、中日经贸交流活动暨氢能产业对接会、中国(吉林)与韩国经贸交流会 等，深入开展项目推介和产业对接，进一步提升了氢能等领域的合作水平。 马坚介绍，第九届东北亚智库对话会、2025吉遇浙里—长三角知名企业家走进吉林暨吉林省冰雪装备产 业发展科技创新对接活动、第八届长白山医药健康产业发展对接会等，形成一系列合作成果。"我们将 持续巩固和拓展大会 ...

至于生物制药，很多人以为这是高科技，其实认真看，特别大的生物制药公司并不是特别多，在中国因为政府的干预，把医药产品，炒出天价，成为垄断或 是奇货可居，基本是不存在的，所以即使有社会需求，但是它不可能成为高毛利产品。这点中国和美国很大不同。 随着生活品质提升，人们重视营养，重视锻练，重视饮食的调节，日常生活中，并不是生物制药的支出增加，而应该是减少或是持平的。即使重大疾病，比 如要换个肝，也不是一般人的日常，而且国家也不会允许天价。这样看生物制药并不会因为生活水平改善，我们就要吃更多的药，在看病上花更多的钱。 如果中国不面临重大战争，出现重大社会危机（我相信可能性极小），再过5-10年，中国经济实力更强，人民生活更好，大家应该还是可以喝更多的酒，而 不是吃更多的药，所以我还是相信生物制药的产业前途并不那么光明。 , ,, 个人观点，仅供参考 今天有朋友问我，未来5-10年，股市我是看好白酒产业，还是看好生物医药？ 我并不研究股市，只关注产业，不过如果要说未来10年，股市的情况，我还是更看好白酒产业，道理并不复杂，白酒是大众消费品，这也是商务消费和日常 生活的重要组成部分，只要有宴请，有社交，有商务活动，总是要喝 ...

Core Viewpoint - The series of regional expos in China are becoming vital platforms for global business opportunities, international cooperation, and sharing China's economic prospects, contributing significantly to the recovery and development of the world economy [1][4]. Group 1: Regional Expos Overview - China has hosted various regional expos this year, including the 15th China-Northeast Asia Expo and the 7th China-Arab States Expo, showcasing a vibrant "exhibition matrix" that spans from north to south and east to west [1]. - These expos serve as innovative platforms that go beyond traditional trade, integrating new technologies and business models, exemplified by the establishment of the "Silk Road E-commerce" cooperation conference at the China-Arab Expo [3]. Group 2: Market Potential and Opportunities - China's large population of over 1.4 billion and the expanding middle-income group position it as a significant market with immense potential, further enhanced by the ongoing digital, intelligent, and green consumption transformations [2]. - The expos provide valuable opportunities for foreign enterprises to explore the Chinese market and share in its development dividends, as highlighted by various international media [2]. Group 3: Economic Impact and Cooperation - The 9th China-South Asia Expo signed 31 investment cooperation projects with a total investment of 13.609 billion yuan, marking a 33% increase from the previous session [4]. - The 4th China-Central and Eastern Europe Expo facilitated over 80 procurement and trade promotion activities, with import orders amounting to 10.98 billion yuan [4]. - These events exemplify a collaborative approach to overcoming global economic challenges, emphasizing China's commitment to open cooperation and mutual benefits [4][5].

2024年1至12月份，成大生物的营业收入构成为：生物制药占比100.0%。 每经头条（nbdtoutiao）——A股成交连续8天破2万亿元，券商招聘也来了！行业巨头秋招"求才"，25个 岗位都有什么特点？ （记者 张喜威） 截至发稿，成大生物市值为123亿元。 每经AI快讯，成大生物（SH 688739，收盘价：29.47元）8月25日晚间发布公告称，2025年8月25日，公 司通过集中竞价交易方式首次回购公司股份约4.4万股，占公司总股本约4.16亿股的比例约为0.0106%， 回购成交的最高价为29.61元/股，最低价为29.2元/股，支付的资金总额为人民币约129万元。 ...

2024年1至12月份，成大生物的营业收入构成为：生物制药占比100.0%。 （文章来源：每日经济新闻） 成大生物（SH 688739，收盘价：28.77元）8月12日晚间发布公告称，公司第五届第二十一次董事会会 议于2025年8月12日以现场和通讯相结合的方式召开。会议审议了《关于补选公司董事的议案》等文 件。 ...

Group 1 - The core point of the article is that Chengda Biological has announced the progress of its share repurchase plan, stating that as of July 31, 2025, the company has not yet implemented this plan and will decide on the timing based on market conditions [2] - For the year 2024, Chengda Biological's revenue composition is entirely from biopharmaceuticals, accounting for 100.0% [2]

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., anticipates a significant increase in revenue for the first half of 2025, despite reporting a net loss attributed to various operational challenges [1][2]. Financial Performance Summary - Expected operating revenue for the period is projected to be approximately 105.81 million yuan, representing a year-on-year growth of 70.12% to 79.57% [1]. - The net loss attributable to shareholders is estimated to be between 9 million to 13 million yuan, compared to a loss of 11.06 million yuan in the same period last year, indicating a decrease of 17.56% to 18.61% [1]. - The net loss after deducting non-recurring gains and losses is expected to be between 10 million to 14 million yuan, a decline of 42.75% to 1.96% compared to a loss of 9.81 million yuan last year [1]. - Basic earnings per share are projected to be between -0.0126 yuan and -0.0087 yuan, compared to -0.0107 yuan per share in the previous year [1]. Reasons for Performance Changes - The primary reason for the company's losses is a slight decline in revenue from its subsidiary, Beijing Sihuan Biological Pharmaceutical Co., Ltd., along with increased management expenses due to legal fees related to a securities fraud case [2]. - Conversely, the increase in operating revenue is attributed to a strategic cooperation agreement between its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., and Jiangyin Xinganfa Trading Co., Ltd., leading to a substantial rise in sales of seedlings [2]. Other Relevant Information - The performance forecast is based on preliminary estimates from the company's finance department, with final figures to be confirmed in the official half-year report for 2025 [2].

Group 1 - China's economy is showing resilience and stability in growth despite external shocks and internal challenges, attracting significant international attention [1] - The strategy of strengthening the domestic circulation aims to enhance China's economic self-reliance by building a strong and unified domestic market, which is seen as a long-term vision [4] - The domestic consumption market is experiencing steady growth driven by new business models and trends, with particular attention on two sectors: products influenced by the "trade-in" policy and service consumption supported by financial and policy incentives [6] Group 2 - China is advancing towards the global forefront of technological innovation through investment in talent and ecosystem development, with significant achievements in various fields such as AI, space exploration, and renewable energy [8] - The integration of technology and industrial innovation in China is reshaping its industrial landscape and contributing to global development by providing new solutions to address the "development deficit" faced by many countries [10]

Core Insights - South Korea's exports unexpectedly increased in April due to strong semiconductor sales, despite challenges in the automotive sector from U.S. tariffs [1] Group 1: Export Performance - In April, South Korea's export value reached $58.21 billion, marking a 3.7% year-on-year increase, which is the largest growth in four months [1] - This growth exceeded market expectations, which had a median forecast of 2.0% [1] - Semiconductor exports rose by 17.2%, representing the largest increase in four months, while steel product exports grew by 5.4%, ending a three-month decline [1] Group 2: Sector-Specific Trends - Automotive exports declined by 3.8%, although automotive parts saw a 3.5% increase [1] - Wireless communication devices and biopharmaceutical products experienced significant growth, with increases of 26.5% and 21.8% respectively [1] Group 3: Trade Relationships - Exports to the United States fell by 6.8%, while exports to the European Union surged by 18.4%, reaching a record $6.7 billion [1] - South Korea is the first major exporting economy to release trade data each month, providing early insights into global trade conditions [1]